MetaCap

Quantum Cyber N.V. (QUCY)

NASDAQ: QUCYHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.512-0.04 (-7.25%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

QUCY stock chart

Technical analysis

Key statistics

All statistics
Market cap
$44.67M
EPS (TTM)
-$2.27
52-week range
0.30 – 4.93
Day range
0.5108 – 0.5786
Volume / Avg
301.92K / 528.02K
Beta
—

52-week range

$0.30$4.93

QUCY stock today

On Nov 20, QUCY ended the session at $0.512, shedding $0.04 (7.25%), versus the S&P 500's 3.70% decline. At this level, QUCY sits near the bottom of its 52-week range of $0.30 to $4.93: 89.6% below the high, set on May 15, 2026 and 70.7% above the low. QUCY is down 54.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 48.7%.

Quantum Cyber N.V. has posted a net loss over the last twelve months (EPS of -$2.27), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Quantum Cyber N.V.

Company profile

Quantum Cyber N.V. operates as a technology company focused on cybersecurity and quantum computing solutions. The company pursues acquisitions and partnerships in areas including post-quantum cryptography, zero-trust architecture, and national security technologies.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. David Elliot Lazar
Headquarters
Mainz
Employees
10
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Quantum Cyber N.V. generated $537,080 in revenue, down 39.9% from fiscal 2024, its first annual decline since 2024. Quantum Cyber N.V. reported a net loss of $16.2 million, compared with a loss of $21.6 million a year earlier. Gross margin was 72.6% (up from 64.3%) and operating margin -3005.0%.

Quantum Cyber N.V. annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$537.08K$893.99K$895.48K$529.88K$577.35K
Growth-39.92%-0.17%+69.00%-8.22%+16.98%
Net income$-16.21M$-21.60M$-26.34M$-26.39M$-11.69M
EPS (diluted)$-2.70$-21.91$-64.76$-74.55$-1.62

Analyst forecast

Forecast

Consensus (2 analysts)

none

Avg. price target

$9.00+1657.81%

  • Strong buy 0
  • Buy 1
  • Hold 1
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.08 vs $-0.08

QUCY news

All QUCY news

Quantum Cyber N.V. peers

Health Care sector
QUCY peer companies
CompanyPrice% ChgMarket capCompare
GANXGain Therapeutics Inc.0.9994-4.82%$44.50Mvs QUCY
ANVSAnnovis Bio Inc.0.7113-4.96%$44.12Mvs QUCY
APLMApollomics Inc. Class A15.54-6.92%$45.28Mvs QUCY
RNXTRenovoRx Inc.0.942-10.29%$45.45Mvs QUCY
HOWLWerewolf Therapeutics Inc.0.9466-3.97%$46.00Mvs QUCY
RLYBRallybio Corporation15.47-0.32%$43.32Mvs QUCY
SPROSpero Therapeutics Inc.0.742-10.20%$43.23Mvs QUCY
MISTMilestone Pharmaceuticals Inc.0.3711-7.06%$46.20Mvs QUCY

Indexes, lists and sector

Quantum Cyber N.V. stock FAQ

What is Quantum Cyber N.V.'s stock price today?

QUCY last traded at $0.512 as of Nov 20, 4:00 PM EST, down 7.25% on the day. Prices are delayed at least 15 minutes.

Who is Quantum Cyber N.V.'s CEO?

Mr. David Elliot Lazar is the chief executive officer of Quantum Cyber N.V., which has about 10 employees.

What is the QUCY 52-week high?

The 52-week high for QUCY is $4.93 and the 52-week low is $0.30. The stock is currently 89.6% below its high.

Compare QUCY